Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

Monoclonal antibodies can block cellular interactions that negatively regulate T-cell immune responses, such as CD80/CTLA-4 and PD-1/PD1-L, amplifying preexisting immunity and thereby evoking antitumor immune responses. Ibrutinib, an approved therapy for B-cell malignancies, is a covalent inhibitor...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Proc Natl Acad Sci U S A
Main Authors: Sagiv-Barfi, Idit, Kohrt, Holbrook E. K., Czerwinski, Debra K., Ng, Patrick P., Chang, Betty Y., Levy, Ronald
Format: Artigo
Sprog:Inglês
Udgivet: National Academy of Sciences 2015
Fag:
PNAS Plus
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352777/
https://ncbi.nlm.nih.gov/pubmed/25730880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1500712112
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker